How do glucocorticoids cause hypertension: Role of nitric oxide deficiency, oxidative stress, and eicosanoids

Endocrinology and Metabolism Clinics of North America

Volumn 40, Issue 2, 2011, Pages 393-407

  Ong, Sharon L H ^a,b   Whitworth, Judith A ^c  

^a ST GEORGE HOSPITAL   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c Biology and Environment   (Australia)

Author keywords

20 hydroxyeicosatetranoic acid; Glucocorticoid; Hypertension; Nitric oxide; Oxidative stress; Prostanoids

Indexed keywords

ACETYLCYSTEINE; ACETYLSALICYLIC ACID; ANGIOTENSIN II; APOCYNIN; ARGININE; ARGIPRESSIN; ATENOLOL; ATORVASTATIN; CORTICOTROPIN; DEXAMETHASONE; ENDOTHELIN; FELODIPINE; FOLIC ACID; GLUCOCORTICOID; GUANOSINE TRIPHOSPHATE CYCLOHYDROLASE I; HYDROCORTISONE; ICOSANOID; LOSARTAN; MESSENGER RNA; MINOXIDIL; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE INHIBITOR; PREDNISOLONE; RAMIPRIL; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; SPIRONOLACTONE; TETRAHYDROBIOPTERIN; TRIAMCINOLONE; UNINDEXED DRUG; XANTHINE OXIDASE;

DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG MECHANISM; DRUG MEGADOSE; DRUG TREATMENT FAILURE; ENZYME INHIBITION; ENZYME REGULATION; HEMODYNAMICS; HUMAN; HYPERTENSION; NONHUMAN; OUTCOME ASSESSMENT; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; VASCULAR RESISTANCE;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CUSHING SYNDROME; EICOSANOIDS; GLUCOCORTICOIDS; HUMANS; HYPERTENSION; IATROGENIC DISEASE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE III; OXIDATIVE STRESS;

ANIMALIA;

EID: 79955726640     PISSN: 08898529     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ecl.2011.01.010     Document Type: Review

References (91)

1. Ross E.J., Linch D.C. Cushing's syndrome-killing disease: discriminatory value of signs and symptoms aiding early diagnosis. Lancet 1982, 320:646-649.
2. Treadwell B.L., Sever E.D., Savage O., et al. Side-effects of long-term treatment with corticosteroids and corticotrophin. Lancet 1964, 283:1121-1123.
3. Savage O., Copeman W.S., Chapman L., et al. Pituitary and adrenal hormones in rheumatoid arthritis. Lancet 1962, 279:232-235.
4. Mangos G.J., Turner S.W., Fraser T.B., et al. The role of corticosterone in corticotrophin (ACTH)-induced hypertension in the rat. J Hypertens 2000, 18:1849-1855.
5. Pirpiris M., Yeung S., Dewar E., et al. Hydrocortisone-induced hypertension in men. The role of cardiac output. Am J Hypertens 1993, 6:287-294.
6. Connell J.M., Whitworth J.A., Davies D.L., et al. Effects of ACTH and cortisol administration on blood pressure, electrolyte metabolism, atrial natriuretic peptide and renal function in normal man. J Hypertens 1987, 5:425-433.
7. Kelly J.J., Tam S.H., Williamson P.M., et al. The nitric oxide system and cortisol-induced hypertension in humans. Clin Exp Pharmacol Physiol 1998, 25:945-946.
8. Hu L., Zhang Y., Lim P.S., et al. Apocynin but not l-arginine prevents and reverses dexamethasone-induced hypertension in the rat. Am J Hypertens 2006, 19:413-418.
9. Zhang Y., Croft K.D., Mori T.A., et al. The antioxidant tempol prevents and partially reverses dexamethasone-induced hypertension in the rat. Am J Hypertens 2004, 17:260-265.
10. Krug S., Zhang Y., Mori T.A., et al. N-Acetylcysteine prevents but does not reverse dexamethasone-induced hypertension. Clin Exp Pharmacol Physiol 2008, 35:979-981.
11. Nakamoto H., Suzuki H., Kageyama Y., et al. Characterization of alterations of hemodynamics and neuroendocrine hormones in dexamethasone induced hypertension in dogs. Clin Exp Hypertens A 1991, 13:587-606.
12. Nakamoto H., Suzuki H., Kageyama Y., et al. Depressor systems contribute to hypertension induced by glucocorticoid excess in dogs. J Hypertens 1992, 10:561-569.
13. Pirpiris M., Sudhir K., Yeung S., et al. Pressor responsiveness in corticosteroid-induced hypertension in humans. Hypertension 1992, 19:567-574.
14. Scoggins B.A., Allen K.J., Coghlan J.P., et al. Haemodynamics of ACTH-induced hypertension in sheep. Clin Sci (Lond) 1979, 57(Suppl 5):333s-336s.
15. Turner S.W., Wen C., Li M., et al. Adrenocorticotrophin dose-response relationships in the rat: haemodynamic, metabolic and hormonal effects. J Hypertens 1998, 16:593-600.
16. Whitworth J.A. Adrenocorticotrophin and steroid-induced hypertension in humans. Kidney Int Suppl 1992, 37:S34-S37.
17. Ong S.L., Zhang Y., Sutton M., et al. Hemodynamics of dexamethasone-induced hypertension in the rat. Hypertens Res 2009, 32:889-894.
18. Whitworth J.A., Williamson P.M., Ramsey D. Haemodynamic response to cortisol in man: effects of felodipine. Hypertens Res 1994, 17:137-142.
19. Wen C., Fraser T., Li M., et al. Hemodynamic profile of corticotropin-induced hypertension in the rat. J Hypertens 1998, 16:187-194.
20. Wen C., Fraser T., Li M., et al. Haemodynamic mechanisms of corticotropin (ACTH)-induced hypertension in the rat. J Hypertens 1999, 17:1715-1723.
21. Montrella-Waybill M., Clore J.N., Schoolwerth A.C., et al. Evidence that high dose cortisol-induced Na+ retention in man is not mediated by the mineralocorticoid receptor. J Clin Endocrinol Metab 1991, 72:1060-1066.
22. Williamson P.M., Kelly J.J., Whitworth J.A. Dose-response relationships and mineralocorticoid activity in cortisol-induced hypertension in humans. J Hypertens 1996, Suppl 14:S37-S41.
23. Li M., Wen C., Fraser T., et al. Adrenocorticotrophin-induced hypertension: effects of mineralocorticoid and glucocorticoid receptor antagonism. J Hypertens 1999, 17:419-426.
24. Whitworth J.A., Saines D., Scoggins B.A. Potentiation of ACTH hypertension in man with salt loading. Clin Exp Pharmacol Physiol 1985, 12:239-243.
25. Connell J.M., Whitworth J.A., Davies D.L., et al. Haemodynamic, hormonal and renal effects of adrenocorticotrophic hormone in sodium-restricted man. J Hypertens 1988, 6:17-23.
26. Macefield V.G., Williamson P.M., Wilson L.R., et al. Muscle sympathetic vasoconstrictor activity in hydrocortisone-induced hypertension in humans. Blood Press 1998, 7:215-222.
27. Tabarin A., Minot A.P., Dallochio M., et al. Plasma concentration of neuropeptide Y in patients with adrenal hypertension. Regul Pept 1992, 42:51-61.
28. Whitworth J.A., Williamson P.M., Mangos G., et al. Cardiovascular consequences of cortisol excess. Vasc Health Risk Manag 2005, 1:291-299.
29. Borcsok I., Schairer H.U., Sommer U., et al. Glucocorticoids regulate the expression of the human osteoblastic endothelin A receptor gene. J Exp Med 1998, 188:1563-1573.
30. Takahashi K., Suda K., Lam H.C., et al. Endothelin-like immunoreactivity in rat models of diabetes mellitus. J Endocrinol 1991, 130:123-127.
31. Iijima F., Malik K.U. Contribution of vasopressin in dexamethasone-induced hypertension in rats. Hypertension 1988, 11:I42-I46.
32. Murasawa S., Matsubara H., Kizima K., et al. Glucocorticoids regulate V1a vasopressin receptor expression by increasing mRNA stability in vascular smooth muscle cells. Hypertension 1995, 26:665-669.
33. Saruta T. Mechanism of glucocorticoid-induced hypertension. Hypertens Res 1996, 19:1-8.
34. Wen C., Li M., Fraser T., et al. l-Arginine partially reverses established adrenocorticotrophin-induced hypertension and nitric oxide deficiency in the rat. Blood Press 2000, 9:298-304.
35. Wallerath T., Witte K., Schafer S.C., et al. Down-regulation of the expression of endothelial NO synthase is likely to contribute to glucocorticoid-mediated hypertension. Proc Natl Acad Sci U S A 1999, 96:13357-13362.
36. Zhang Y., Wu J.H., Vickers J.J., et al. The role of 20-hydroxyeicosatetraenoic acid in glucocorticoid-induced hypertension. J Hypertens 2009, 27:1609-1616.
37. Andrews M.C., Schyvens C.G., Zhang Y., et al. Nitric oxide donation lowers blood pressure in adrenocorticotrophic hormone-induced hypertensive rats. Clin Exp Hypertens 2004, 26:499-509.
38. Kelly J.J., Tam S.H., Williamson P.M., et al. Decreased threshold for the nitric oxide donor glyceryl trinitrate in cortisol-induced hypertension in humans. Clin Exp Pharmacol Physiol 2007, 34:1317-1318.
39. Turner S.W., Wen C., Li M., et al. l-Arginine prevents corticotropin-induced increases in blood pressure in the rat. Hypertension 1996, 27:184-189.
40. Li M., Fraser T., Wang J., et al. Dexamethasone-induced hypertension in the rat: effects of l-arginine. Clin Exp Pharmacol Physiol 1997, 24:730-732.
41. Kelly J.J., Williamson P., Martin A., et al. Effects of oral l-arginine on plasma nitrate and blood pressure in cortisol-treated humans. J Hypertens 2001, 19:263-268.
42. Wen C., Li M., Whitworth J.A. Role of nitric oxide in adrenocorticotrophin-induced hypertension: l-arginine effects reversed by N-nitro-l-arginine. Clin Exp Pharmacol Physiol 2000, 27:887-890.
43. Chin-Dusting J.P., Ahlers B.A., Kaye D.M., et al. l-Arginine transport in humans with cortisol-induced hypertension. Hypertension 2003, 41:1336-1340.
44. Li M., Dusting G.J., Whitworth J.A. Inhibition of NO synthesis has an additive effect on hypertension induced by ACTH in conscious rats. Clin Exp Pharmacol Physiol 1992, 19:675-681.
45. Thida M., Earl J., Zhao Y., et al. Effects of sepiapterin supplementation and NOS inhibition on glucocorticoid-induced hypertension. Am J Hypertens 2010, 23:569-574.
46. Wallerath T., Godecke A., Molojavyi A., et al. Dexamethasone lacks effect on blood pressure in mice with a disrupted endothelial NO synthase gene. Nitric Oxide 2004, 10:36-41.
47. Lou Yk, Wen C., Li M., et al. Decreased renal expression of nitric oxide synthase isoforms in adrenocorticotropin-induced and corticosterone-induced hypertension. Hypertension 2001, 37:1164-1170.
48. Schmidt K., Werner E.R., Mayer B., et al. Tetrahydrobiopterin-dependent formation of endothelium-derived relaxing factor (nitric oxide) in aortic endothelial cells. Biochem J 1992, 281(Pt 2):297-300.
49. Alp N.J., Channon K.M. Regulation of endothelial nitric oxide synthase by tetrahydrobiopterin in vascular disease. Arterioscler Thromb Vasc Biol 2004, 24:413-420.
50. Simmons W.W., Ungureanu-Longrois D., Smith G.K., et al. Glucocorticoids regulate inducible nitric oxide synthase by inhibiting tetrahydrobiopterin synthesis and l-arginine transport. J Biol Chem 1996, 271:23928-23937.
51. Johns D.G., Dorrance A.M., Tramontini N.L., et al. Glucocorticoids inhibit tetrahydrobiopterin-dependent endothelial function. Exp Biol Med 2001, 226:27-31.
52. Mitchell B.M., Dorrance A.M., Webb R.C. GTP cyclohydrolase 1 downregulation contributes to glucocorticoid hypertension in rats. Hypertension 2003, 41:669-674.
53. Zhang Y., Pang T., Earl J., et al. Role of tetrahydrobiopterin in adrenocorticotropic hormone-induced hypertension in the rat. Clin Exp Hypertens 2004, 26:231-241.
54. Miao Y., Zhang Y., Lim P.S., et al. Folic acid prevents and partially reverses glucocorticoid-induced hypertension in the rat. Am J Hypertens 2007, 20:304-310.
55. Hong H.-J., Hsiao G., Cheng T.H., et al. Supplementation with tetrahydrobiopterin suppresses the development of hypertension in spontaneously hypertensive rats. Hypertension 2001, 38:1044-1048.
56. Iuchi T., Akaike M., Mitsui T., et al. Glucocorticoid excess induces superoxide production in vascular endothelial cells and elicits vascular endothelial dysfunction. Circ Res 2003, 92:81-87.
57. Zhang Y., Jang R., Mori T.A., et al. The anti-oxidant tempol reverses and partially prevents adrenocorticotrophic hormone-induced hypertension in the rat. J Hypertens 2003, 21:1513-1518.
58. Mondo C.K., Zhang Y., Possamai V., et al. N-Acetylcysteine antagonizes the development but does not reverse ACTH-induced hypertension in the rat. Clin Exp Hypertens 2006, 28:73-84.
59. Mondo C.K., Yang W.S., Zhang N., et al. Anti-oxidant effects of atorvastatin in dexamethasone-induced hypertension in the rat. Clin Exp Pharmacol Physiol 2006, 33:1029-1034.
60. Zhang Y., Chan M.M., Andrews M.C., et al. Apocynin but not allopurinol prevents and reverses adrenocorticotropic hormone-induced hypertension in the rat. Am J Hypertens 2005, 18:910-916.
61. Zhang Y., Miao Y., Whitworth J.A. Aspirin prevents and partially reverses adrenocorticotropic hormone-induced hypertension in the rat. Am J Hypertens 2007, 20:1222-1228.
62. He Y., Zhang Y., Whitworth J.A. Losartan prevents and reverses glucocorticoid-induced hypertension. Hypertension 2009, 53:043.
63. Ong S.L., Vickers J.J., Zhang Y., et al. Role of xanthine oxidase in dexamethasone-induced hypertension in rats. Clin Exp Pharmacol Physiol 2007, 34:517-519.
64. Rajashree S., Puvanakrishnan R. Dexamethasone induced alterations in the levels of proteases involved in blood pressure homeostasis and blood coagulation in rats. Mol Cell Biochem 1999, 197:203-208.
65. Carletti M., Cantiello M., Giantin M., et al. Serum antioxidant enzyme activities and oxidative stress parameters as possible biomarkers of exposure in veal calves illegally treated with dexamethasone. Toxicol In Vitro 2007, 21:277-283.
66. Crawford D.R., Davies K.J. Adaptive response and oxidative stress. Environ Health Perspect 1994, 102(Suppl 10):25-28.
67. Axelrod L. Inhibition of prostacyclin production mediates permissive effect of glucocorticoids on vascular tone. Perturbations of this mechanism contribute to pathogenesis of Cushing's syndrome and Addison's disease. Lancet 1983, 1:904-906.
68. Flower R.J., Blackwell G.J. Anti-inflammatory steroids induce biosynthesis of a phospholipase A2 inhibitor which prevents prostaglandin generation. Nature 1979, 278:456-459.
69. Hirata F., Schiffmann E., Venkatasubramanian K., et al. A phospholipase A2 inhibitory protein in rabbit neutrophils induced by glucocorticoids. Proc Natl Acad Sci U S A 1980, 77:2533-2536.
70. Russo-Marie F., Duval D. Dexamethasone-induced inhibition of prostaglandin production dose not result from a direct action on phospholipase activities but is mediated through a steroid-inducible factor. Biochim Biophys Acta 1982, 712:177-185.
71. Falardeau P., Martineau A. Prostaglandin I2 and glucocorticoid-induced rise in arterial pressure in the rat. J Hypertens 1989, 7:625-632.
72. Handa M., Kondo K., Suzuki H., et al. Urinary prostaglandin E2 and kallikrein excretion in glucocorticoid hypertension in rats. Clin Sci (Lond) 1983, 65:37-42.
73. Zhang Y., Hu L., Mori T.A., et al. Arachidonic acid metabolism in glucocorticoid-induced hypertension. Clin Exp Pharmacol Physiol 2008, 35:557-562.
74. Whitworth J.A., Connell J.M., Gordon D., et al. Effects of indomethacin on steroid-induced changes in pressor responsiveness in man. Clin Exp Pharmacol Physiol 1988, 15:305-310.
75. Miyata N., Roman R.J. Role of 20-hydroxyeicosatetraenoic acid (20-HETE) in vascular system. J Smooth Muscle Res 2005, 41:175-193.
76. Morgan E.T., Ullrich V., Daiber A., et al. Cytochromes P450 and flavin monooxygenases-targets and sources of nitric oxide. Drug Metab Dispos 2001, 29:1366-1376.
77. Alonso-Galicia M., Drummond H.A., Reddy K.K., et al. Inhibition of 20-HETE production contributes to the vascular responses to nitric oxide. Hypertension 1997, 29:320-325.
78. Oyekan A.O., Youseff T., Fulton D., et al. Renal cytochrome P450 omega-hydroxylase and epoxygenase activity are differentially modified by nitric oxide and sodium chloride. J Clin Invest 1999, 104:1131-1137.
79. Sun C.W., Alonso-Galicia M., Taheri M.R., et al. Nitric oxide-20-hydroxyeicosatetraenoic acid interaction in the regulation of K+ channel activity and vascular tone in renal arterioles. Circ Res 1998, 83:1069-1079.
80. Cheng J., Ou J.S., Singh H., et al. 20-Hydroxyeicosatetraenoic acid causes endothelial dysfunction via eNOS uncoupling. Am J Physiol Heart Circ Physiol 2008, 294:H1018-H1026.
81. Wang J.S., Singh H., Zhang F., et al. Endothelial dysfunction and hypertension in rats transduced with CYP4A2 adenovirus. Circ Res 2006, 98:962-969.
82. Lin F., Abraham N.G., Schwartzman M.L. Cytochrome P450 arachidonic acid omega-hydroxylation in the proximal tubule of the rat kidney. Ann N Y Acad Sci 1994, 744:11-24.
83. Sanchez-Mendoza A., Lopez-Sanchez P., Vazquez-Cruz B., et al. Angiotensin II modulates ion transport in rat proximal tubules through CYP metabolites. Biochem Biophys Res Commun 2000, 272:423-430.
84. Whitworth J.A., Gordon D., Andrews J., et al. The hypertensive effect of synthetic glucocorticoids in man: role of sodium and volume. J Hypertens 1989, 7:537-549.
85. Humphrey T.J., Fan J.S., Coghlan J.P., et al. Inter-relationships between sodium and potassium intake and the blood pressure effects of ACTH in sheep. J Hypertens 1983, 1:19-26.
86. Mills E.H., Coghlan J.P., Denton D.A., et al. The effect of sodium depletion and potassium loading on cortisol induced hypertension in sheep. Acta Endocrinol (Copenh) 1986, 113:298-304.
87. Mondo C.K., Yang W.S., Su J.Z., et al. Atorvastatin prevented and reversed dexamethasone-induced hypertension in the rat. Clin Exp Hypertens 2006, 28:499-509.
88. Turner S.W., Mangos G.J., Whitworth J.A. Nitric oxide synthase activity in adrenocorticotrophin-induced hypertension in the rat. Clin Exp Pharmacol Physiol 2001, 28:881-883.
89. Shafagoj Y., Opoku J., Qureshi D., et al. Dehydroepiandrosterone prevents dexamethasone-induced hypertension in rats. Am J Physiol Endocrinol Metab 1992, 263:E210-E213.
90. Li M., Wen C., Martin A., et al. Dehydroepiandrosterone does not prevent adrenocorticotrophin-induced hypertension in conscious rats. Clin Exp Pharmacol Physiol 1996, 23:435-437.
91. Fraser T.B., Turner S.W., Wen C., et al. Vasopressin V1a receptor antagonism does not reverse adrenocorticotrophin-induced hypertension in the rat. Clin Exp Pharmacol Physiol 2000, 27:866-870.